we appreciate you. We appreciate your bravery, your strength, your love for the ones that you lost.
As you know, I am a big supporter of what you do. And we just want to go forward.
Under the current structure, PBMs make more money when a drug's list price increases, while patients bear the financial ...
Our airspace has to manage commercial airliners from Newark Liberty, emergency response, and sightseeing helicopters.
The hyper-consolidation, with little to no regulatory oversight, creates inappropriate negotiating leverage that discour...
This level of concentration gives these PBMs market power over data, drug coverage, and contracting--80 percent.
To have the opportunity to think about these issues with Rudy is going to be an interesting opportunity.
People are really concerned, and they're not all Republicans; they're independents, middle-of-the-roaders. People love w...
PBMs benefit significantly from high list prices and have no incentive to choose lower-priced drugs to drive down patien...
Our reauthorization of user fees should not be seen by the majority or anybody as a justification to cut FDA's budget.
High list prices hurt patients who must pay these prices. If list prices were lower, out-of-pocket payments based on lis...
The two animal user fee programs we are reviewing today support the timely review of both pioneer and generic drugs at t...
Pharmacy benefit managers are key players, or should be, in alleviating patients' financial burden at the pharmacy count...
it is also just fascinating, because I know the area that he represents, northern Indiana.
Would patients be better off if PBMs and other supply chain entities were paid flat fees for the services they provide?
I don't really think you should be criticizing something without an alternative.
The Biden budget also proposes to finally ensure that all low-income individuals have access to the benefits and protect...
Thanks to the Inflation Reduction Act, we finally allowed Medicare to negotiate prescription drug prices.
